🇺🇸

US SEC Filing Intelligence

· daily

Mega Contracts Monitor ($100M+) — August 28, 2026

The August 28, 2026 mega-contract digest aggregates $1.32 billion in obligations across four civilian awards, with zero defense-related contracts. The dominant theme is federal civilian infrastructure and services, led by IBM's $580.4 million FEMA IT delivery order (though with negative outlays, signaling possible inactivity), Hensel Phelps' $374.9 million GSA border port construction, PAE Aviation's $201.7 million DHS aviation maintenance, and OptumRx's $159.2 million VA pharmacy benefits order. The highest-conviction signal is OptumRx's four-month, firm-fixed-price delivery order, which provides near-term revenue certainty and underscores UnitedHealth Group's competitive strength in federal PBM services. Key risks include the negative outlay on IBM's contract, execution risk on Hensel Phelps' fixed-price construction, and the short performance periods on PAE and OptumRx contracts.

4 total filings
· daily

High-Value Federal Grants ($5M+) — August 28, 2026

The six high-value federal grants totaling $1.50 billion are entirely civilian, with zero defense-related awards, underscoring sustained government investment in non-DOD priorities. The Department of Homeland Security dominates the stream with $782.1 million across two contracts, including IBM's $580.4 million FEMA IT delivery order (though with negative outlays) and PAE Aviation's $201.7 million sole-source CBP aviation maintenance award. The highest-conviction signal is OptumRx's $159.2 million VA pharmacy benefit management delivery order, a four-month firm-fixed-price win that annualizes to ~$477.6 million and signals competitive strength in healthcare services. Key risks include potential revenue non-realization on IBM's FEMA contract (negative outlay) and execution risk on Hensel Phelps' $374.9 million fixed-price border construction project over a six-year horizon. Investors should watch for option exercises on Lockheed Martin's Mars Ascent Vehicle contract and any CMS modernization that could threaten Peraton's Medicare claims processing work.

6 total filings
· daily

General Federal Contracts — August 28, 2026

The six contracts analyzed total $1.50 billion in obligations, with zero defense-related awards, underscoring a civilian-heavy procurement week dominated by the Department of Homeland Security ($782.1M combined) and healthcare IT. The highest-conviction signal is a sole-source, $201.7M DHS aviation maintenance award to PAE Aviation (Amentum), reflecting a durable competitive moat in border security logistics. A key risk is the $580.4M IBM-FEMA contract showing negative outlays ($-23,548), suggesting potential revenue recognition issues or contract dormancy. The digest reveals a bifurcated civilian market: stable, high-margin healthcare PBM awards (OptumRx, $159.2M) versus legacy IT infrastructure contracts (IBM, Peraton) with execution uncertainty.

6 total filings
· daily

All NASA Contracts — August 28, 2026

The single NASA contract analyzed for August 28, 2026, totals $99.8 million, with zero defense-related awards, underscoring a purely civilian space exploration focus. The dominant theme is NASA's sustained investment in Mars exploration R&D, led by Lockheed Martin Corp's cost-plus-fixed-fee contract for the Mars Ascent Vehicle Integrated System. The highest-conviction signal is Lockheed's strong competitive position in space vehicle manufacturing, evidenced by a full-and-open competition win with no set-aside. A key risk is the potential for budget cuts or delays to the Mars Sample Return mission, which could impact option exercises and future contract value.

1 total filings
· daily

S&P 500 Financials Sector SEC Filings — August 28, 2026

The 7 filings in the S&P 500 Financials stream for August 28, 2026, reveal a sector marked by significant insider selling, a major shift in commercial mortgage servicing, and stable but leveraged capital structures. Intercontinental Exchange (ICE) saw two top insiders sell a combined ~$858K in stock, while AFLAC's 10% owner Japan Post Holdings sold $1.55M, creating a bearish signal for management conviction. In commercial real estate, a notable theme emerged with the appointment of Argentic Services (backed by Elliott Management) as special servicer for two Wells Fargo CMBS trusts, signaling a potential consolidation and active management of distressed assets. T. Rowe Price's OHA Select Private Credit Fund maintained stable distributions but operates with a high 0.98x debt-to-equity ratio, reflecting the sector's reliance on leverage. No period-over-period financial comparisons or forward-looking guidance were provided in these filings, limiting trend analysis. The overall sentiment is mixed, with capital returns (dividends) being offset by insider selling and leveraged structures.

4 high priority 3 medium 7 total filings
· daily

S&P 500 Energy Sector SEC Filings — August 28, 2026

On an exceptionally quiet trading session for the S&P 500 Energy sector (only 2 filings reviewed), the most significant and actionable development comes from ExxonMobil Holdings Corp, which announced a strategic debt restructuring through the redemption of three series of senior notes totaling significant maturity obligations (2036-2038). This proactive liability management move signals confidence in cash flow generation and a focus on balance sheet optimization, which is bullish for Exxon's credit profile and equity risk premium. Meanwhile, an insider transaction at Texas Pacific Land Corp—a nominal purchase of 1 share by a 10% owner—is analytically neutral but may indicate a lack of insider conviction to add meaningful exposure at current elevated valuations for the royalty trust. The lack of QoQ or YoY financial comparisons in these filings limits trend analysis, but the pre-funding of long-dated debt by Exxon suggests a sector-wide theme of 'liability management over aggressive reinvestment.' The stream is notably quiet, with no earnings calls or guidance updates imminent, making the Exxon catalyst the primary focus for the session.

1 high priority 1 medium 2 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — August 28, 2026

The S&P 500 Consumer Staples sector presents a bifurcated picture this period, with Walmart and Target delivering strong top-line growth but diverging sharply on profitability. Walmart's Q2 FY27 revenue surged 5.9% YoY to $187.9B, yet net income fell 9.4% due to a $1.2B swing in other losses, creating a mixed signal. In contrast, Target's Q2 FY26 net earnings more than doubled to $1.877B, driven by a 170bps gross margin expansion, showcasing operational leverage. The remaining filings (Dollar General, P&G, Altria, McCormick) are governance-focused, with no financial data, indicating a quiet period for corporate actions. A key portfolio-level trend is the divergence in margin performance: Target's cost of sales declined 1.7% despite higher sales, while Walmart's operating income grew 28.8% but was offset by non-operating volatility. Insider activity is absent across all filings, limiting conviction signals. Capital allocation patterns show Target slashing share repurchases by 98.8% to $3M, suggesting a shift toward reinvestment or debt reduction, while Walmart's interest expense fell 79% YoY, improving financial flexibility. The sector's forward-looking data is sparse, but scheduled events like P&G's AGM on Oct 13, 2026, and McCormick's Audit Committee transition on Sep 1, 2026, provide near-term catalysts. Overall, the sector shows resilience in revenue but requires careful stock selection due to divergent earnings quality and capital allocation strategies.

6 high priority 1 medium 7 total filings
· daily

S&P 500 Industrials Sector SEC Filings — August 28, 2026

The five filings from S&P 500 Industrials constituents reveal a sector focused on financial stability and capital management, with no major operational surprises. Lockheed Martin and Boeing both secured new revolving credit facilities, signaling proactive liquidity management amid a rising-rate environment, though neither drew on the new lines. Insider activity was mixed: a Parker-Hannifin executive exercised options but sold a portion of shares for tax purposes, a neutral-to-slightly-bearish signal, while a 10% owner of Republic Services made a significant $51.8M open-market purchase, a strong bullish vote of confidence. General Dynamics saw a major holder, Longview Asset Management, file an amended 13D indicating a potential sale of up to 3.4M shares for portfolio diversification, introducing a modest overhang. Period-over-period comparisons were not available in the filings, but the capital allocation and insider patterns suggest a sector where management is confident in creditworthiness but selective in deploying personal capital. The overall theme is one of stability and measured positioning, with Republic Services standing out as a clear alpha opportunity.

5 high priority 5 total filings
· daily

US Material Events SEC 8-K Filings — August 28, 2026

The August 28, 2026, filing cycle reveals a market landscape dominated by significant capital markets activity, corporate restructuring, and strategic pivots. A clear theme is the aggressive pursuit of capital through debt and equity, with companies like Karman Holdings ($100M loan), Boeing (new $2.25B facility), and Lockheed Martin ($2.25B facility) securing substantial credit lines, while smaller firms like Pluri Inc. and BranchOut Food conduct dilutive offerings. This suggests a bifurcated market where large, investment-grade companies are optimizing liquidity, while smaller, cash-strapped firms are forced into more expensive financing. The M&A landscape is active but with notable failures, as seen in the mutual termination of the Element Solutions/Solstice merger, contrasting with the successful completion of Energy Fuels' $243M acquisition of ASM and BitGo's acquisition of NYDIG's trading business. A significant risk cluster is forming around companies with distressed financials, including BioXcel Therapeutics' Chapter 11 filing, Direct Digital Holdings' repeated loan amendments, and Getty Images' $92.3M adverse judgment. Insider activity is sparse in the filings, but the executive compensation patterns at Hycroft Mining and Latch, Inc. indicate a focus on retention. The overall sentiment is cautious, with a high volume of neutral filings masking underlying financial stress and strategic realignment across sectors.

50 high priority 50 total filings
· daily

Insider Trading Pulse — August 28, 2026

Today's insider trading filings reveal a mixed but actionable picture. A significant cluster of open-market purchases by CEOs at 17 Education & Technology Group and Matador Resources signals strong management conviction, while a wave of large-scale sales by senior executives at IBM, Alcoa, and Caesars Entertainment raises caution. The period-over-period data shows a notable uptick in insider buying activity compared to the prior week, with three bullish transactions versus one in the same period last month. However, the aggregate dollar value of insider sales ($8.5M) dwarfs purchases ($70K), indicating a net bearish bias. The most critical development is the $5.76M sale by IBM's SVP, which, combined with the CEO's phantom stock acquisition, creates a nuanced signal. Sector-wise, consumer discretionary and technology show the highest insider selling pressure, while energy and education technology exhibit insider buying. The data suggests investors should closely monitor the divergence in insider behavior across sectors for portfolio rebalancing opportunities.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — August 28, 2026

The seven filings from Dow 30 constituents reveal a mixed picture for the index. Walmart's Q2 FY27 revenue growth of 5.9% YoY to $187.9B demonstrates robust top-line performance, but a 9.4% decline in net income and a swing to $1.2B in other losses highlight earnings quality concerns. Insider activity at IBM shows contrasting signals: the CEO's $2M phantom stock acquisition signals confidence, while an SVP's $5.76M stock sale raises caution. Boeing's new $364-day credit facility, with rates tied to its credit ratings, suggests ongoing liquidity management amid operational challenges. Procter & Gamble's proxy filings indicate stable governance with a 33% female and 50% racially diverse board, but three shareholder proposals signal governance tensions. Salesforce's insider gifting of 16,000 shares under a 10b5-1 plan is a neutral portfolio adjustment. Overall, the portfolio shows revenue growth but margin pressure, with insider activity providing mixed signals on management conviction.

6 high priority 1 medium 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 28, 2026

The USA Corporate Distress & Bankruptcy stream for August 28, 2026, reveals a severe wave of Nasdaq and NYSE American non-compliance events, with 14 filings concentrated on going concern warnings, delisting notices, and bankruptcy proceedings. The most critical development is the Chapter 11 filing of BioXcel Therapeutics, which has entered a stalking horse asset sale to Teva Pharmaceuticals for $57.5 million upfront, signaling a distressed exit for a biotech firm. A dominant theme is the cascade of Nasdaq minimum bid price and stockholders' equity failures, with 10 out of 14 companies receiving deficiency or delisting notices, many of which have already exhausted reverse stock split options (e.g., KALA BIO, GeoVax Labs). Period-over-period comparisons are limited due to the nature of the filings (8-Ks), but the data shows a clear pattern of deteriorating equity positions—My Size, Inc. reported equity of $2.347 million (below the $2.5 million threshold), and Oragenics Inc. reported $3.7 million (below $4 million). Insider trading activity is absent across all filings, which is a notable bearish signal as it suggests a lack of management confidence or an inability to trade due to blackout periods. Forward-looking statements are dominated by compliance plan deadlines and appeal processes, with no positive guidance revisions. The market implications are stark: a potential delisting wave could reduce liquidity and access to capital for these firms, while the BioXcel and Sangamo Therapeutics bankruptcies highlight the ongoing distress in the biotech sector. Portfolio-level patterns indicate that biotech and small-cap tech firms are the most vulnerable, with 6 out of 14 filings from biotech companies.

14 high priority 14 total filings
· daily

Global High-Priority Regulatory Events — August 28, 2026

This digest covers 50 filings from August 28, 2026, dominated by a surge in Nasdaq delisting and deficiency notices (11 filings), signaling a severe liquidity and compliance crisis among small-cap biotech and tech firms. The most material event is BioXcel Therapeutics' Chapter 11 bankruptcy filing with a $57.5M stalking horse bid from Teva Pharmaceuticals, creating a high-stakes auction process. In M&A, a major theme is the consolidation of the Indian cement sector via the ACC/Ambuja Cements amalgamation, alongside a significant $1.76B investment by Hero MotoCorp in EV maker Ather Energy. The SPAC sector shows continued stress, with Constellation Acquisition Corp I using its 7th extension and Allegro Merger Corp terminating its merger with SeeQC. A notable positive trend is the strong revenue growth at Cloud Wave Technologies (191% over two years) being acquired by AXISCADES, and Alara Resources Ltd's revenue surging 909% YoY, attracting investment from South West Pinnacle. Insider activity is limited in these filings, but the sheer volume of going concern and delisting risks points to a broad market cleansing event for micro-cap stocks.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — August 28, 2026

Today's digest reveals a market bifurcated between sectors facing headwinds and those with strong catalysts. The tanker and shipping sector is under pressure, with Hafnia Ltd reporting a 24.8% decline in net income, while the cybersecurity and AI infrastructure spaces show robust growth, exemplified by SentinelOne's 20.5% revenue increase. A significant wave of M&A and restructuring activity is reshaping the landscape, highlighted by BioXcel Therapeutics' Chapter 11 filing and BitGo's acquisition of NYDIG's trading business. Insider activity is mixed, with a notable CEO purchase in the struggling EdTech sector and routine tax-related sales at Marzetti Co. Capital allocation trends show a preference for share buybacks, with News Corp and Southern First Bancshares announcing new programs, while the IPO market shows signs of life with NorthStrive Acquisition Corp's $100M SPAC IPO. The most critical development is the NMPA approval of HUTCHMED's ATLED® for cholangiocarcinoma, a major catalyst for the biotech sector. Portfolio-level patterns indicate a defensive shift in capital allocation towards liquidity and debt management, as seen with Lockheed Martin's new credit facility and JBG SMITH's credit agreement amendment.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — August 28, 2026

The S&P 500 Consumer Discretionary sector saw a quiet session with only three filings, dominated by TJX Companies' strong Q2 FY27 results. TJX reported 5.4% YoY net sales growth to $15.18B and a 22.3% net income surge to $1.52B, driven by improved margins and robust operating cash flow (+53% YoY to $3.35B in H1). The company continued aggressive capital returns ($1.4B buybacks, $1.0B dividends in H1) while increasing capex 21% YoY, signaling confidence in growth. YUM Brands filings were purely administrative—a routine board committee assignment and a phantom stock grant to a new director—with no financial or strategic impact. The key portfolio-level trend is TJX's outperformance in a potentially challenging retail environment, with margin expansion and strong cash generation contrasting with typical sector headwinds. No other companies in the fixed list filed material reports, making TJX the sole actionable focus for investors.

3 high priority 3 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — August 28, 2026

The two filings from Edwards Lifesciences Corp, both dated August 28, 2026, present a mixed but low-materiality picture for this S&P 500 Healthcare component. The first filing (8-K) announces the planned retirement of a senior executive, Donald E. Bobo, Jr., by mid-2027, a routine leadership transition with no immediate financial impact. The second filing (Form 4) reveals an insider sale by a regional vice president, Bruls Annette, of approximately $238,000 worth of stock at $89.98 per share. While the insider sale carries a negative sentiment, its relatively small size and the absence of any broader period-over-period financial trends, guidance changes, or capital allocation actions in these filings limit the depth of portfolio-level insights. The key takeaway is a minor bearish signal from insider activity, offset by a neutral executive transition, with no sector-wide themes emerging from this limited data set.

2 high priority 2 total filings
· daily

US Earnings Financial Results SEC Filings — August 28, 2026

This digest covers 22 enriched SEC filings centered on financial results and earnings, revealing a bifurcated market. Big-cap tech and consumer cyclicals (e.g., Marvell, Autodesk, Gap, Target) posted robust revenue growth and substantial margin expansion, while homebuilders (Hovnanian, Toll Brothers) faced a clear slowdown amid rising rates and inventory adjustments. Several small-cap and pre-revenue life sciences firms showed signs of extended cash burn and operational distress (SeeQC, First Breach), though some, like Anavex, improved cash positions through equity offerings. Insider activity was overall muted, with no major buying or selling across the set, except for strong capital returns via buybacks at Williams-Sonoma and Gap. A dominant theme is 'margin bifurcation,' where 6 out of 17 newly filed companies saw gross margin expand by more than 200 bps, while 3 saw significant compression, making stock selection around cost control a key differentiator. The homebuilding sector is a notable risk area, with two major builders showing double-digit percentage declines in net income.

22 high priority 22 total filings
· daily

US Executive Compensation Proxy SEC Filings — August 28, 2026

This batch of 14 DEF 14A proxy filings reveals a broad market landscape dominated by governance housekeeping and capital structure maneuvers, with a notable cluster of micro-cap companies urgently seeking reverse stock splits to maintain Nasdaq listing compliance. The most critical development across the filings is the prevalence of dilutive proposals: three companies (Bone Biologics, Getty Images, and Profusa) are seeking reverse stock splits, and NN Inc. is doubling its authorized shares, signaling significant future equity needs. Period-over-period data was sparse as these are governance filings, but the insider activity and forward-looking statements provide actionable intelligence. Procter & Gamble stands out as a high-quality governance play with diverse director nominees and a shareholder-friendly stance, while MillerKnoll presents a mixed picture with solid operational progress against a challenging macro backdrop. A pattern of administrative and compliance-driven meetings (Kurv ETF, CBRE Global Real Estate Income Fund, Korea Fund) suggests low materiality for most filings, but the concentrated insider ownership at National Beverage Corp (73.2% CEO ownership) and the urgency of reverse splits at Bone Biologics and Profusa create specific high-conviction signals for risk-aware investors.

14 high priority 14 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 28, 2026

The August 28, 2026 IPO pipeline is dominated by a wave of new S-1 registrations, including four blank-check companies (Graf Industrial Corp. II, and Talawar Tx Inc. via an S-4 de-SPAC), and diverse operating businesses such as Off The Hook YS (NXB) and Amaero Inc. A major M&A event is the $1.6B all-stock acquisition of Supernus Pharmaceuticals by Indivior, creating a diversified neuroscience leader (Indivior/Supernus S-4). Financially, Off The Hook YS shows strong revenue growth (+21% YoY) but a sharp swing to net losses, with operating expenses surging 180% in H1 2026. Several smaller biotech issuers (Sunshine Biopharma, Adaptin Bio) face existential risks related to Nasdaq compliance and cash burn. The pipeline illustrates a bifurcated market: high-growth companies entering public markets despite deteriorating profitability, while distressed issuers attempt to access capital to survive. Key trends include increasing use of complex equity structures (multiple share classes, warrants) and a continued reliance on SPACs for going public.

11 high priority 11 total filings
· daily

US SEC Trading Suspension Halt Orders — August 28, 2026

This digest covers 12 filings related to US trading suspensions, delistings, and regulatory halts, all concentrated on August 24-28, 2026. A dominant theme is the wave of Nasdaq non-compliance notices, with 10 of 12 filings involving Nasdaq-listed companies facing issues ranging from late filings (Netcapital, Gulf Resources, Shuttle Pharmaceuticals, AiRWA) to bid price deficiencies (KALA BIO, GeoVax, Jupiter Neurosciences, BioAtla) and equity shortfalls (My Size, Socket Mobile). Notably, BioAtla received a final delisting affirmation from Nasdaq's Listing Council, with trading suspended effective August 31, 2026, marking the most severe outcome. The filings reveal a pattern of companies exhausting compliance extensions and reverse stock splits, only to face accelerated delisting procedures. Insider activity data was sparse across filings, but the absence of insider buying in the face of these notices is a bearish signal. The aggregate trend shows a tightening regulatory environment, with Nasdaq increasingly denying second chances to companies that have already used reverse splits or failed to meet alternative listing standards. The only non-Nasdaq filing, Oragenics on NYSE American, underscores that exchange compliance pressures are broad-based. Overall, the stream signals heightened delisting risk for micro-cap and pre-revenue biotech/pharma companies, with potential for significant price dislocations and forced selling.

12 high priority 12 total filings